Industry Strength Score
36/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INVENTIVA SA (6IV.DE) Stock Price & Overview
FRA:6IV • FR0013233012
Current stock price
4.77 EUR
+0.14 (+3.14%)
Last:
The current stock price of 6IV.DE is 4.77 EUR. Today 6IV.DE is up by 3.14%. In the past month the price decreased by -10.51%.
6IV.DE Key Statistics
1-Month Range4.625 - 5.69
Current 6IV.DE stock price positioned within its 1-month range.
- Market Cap
- 990.777M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.29
- Dividend Yield
- N/A
6IV.DE Stock Performance
Today
+3.14%
1 Week
-9.49%
1 Month
-10.51%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
6IV.DE Stock Chart
6IV.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 6IV.DE.
Chartmill TA Rating
Chartmill Setup Rating
6IV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE. 6IV.DE may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
6IV.DE Earnings
Next Earnings DateMay 25, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
6IV.DE Forecast & Estimates
16 analysts have analysed 6IV.DE and the average price target is 12.99 EUR. This implies a price increase of 172.41% is expected in the next year compared to the current price of 4.77.
For the next year, analysts expect an EPS growth of 40.18% and a revenue growth -73.92% for 6IV.DE
Analysts
Analysts88.75
Price Target12.99 (172.33%)
EPS Next Y40.18%
Revenue Next Year-73.92%
6IV.DE Financial Highlights
Over the last trailing twelve months 6IV.DE reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS increased by 22.23% compared to the year before.
Income Statements
Revenue(TTM)4.48M
Net Income(TTM)-354.14M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -141.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%66.34%
Sales Q2Q%-100%
EPS 1Y (TTM)22.23%
Revenue 1Y (TTM)-51.26%
6IV.DE Ownership
Ownership
Inst Owners38.4%
Shares207.71M
Float143.16M
Ins Owners4.48%
Short Float %N/A
Short RatioN/A
6IV.DE Industry Overview
6IV.DE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.6
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
6IV.DE Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.81 | 41.543B | ||
| 1AE | ARGENX SE | 28.79 | 41.518B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.443B | ||
| ABVX | ABIVAX SA | N/A | 7.648B | ||
| 2X1 | ABIVAX SA | N/A | 7.64B | ||
| GLPG | GALAPAGOS NV | N/A | 1.591B | ||
| GXE | GALAPAGOS NV | N/A | 1.59B | ||
| NANO | NANOBIOTIX | N/A | 1.39B | ||
| PHARM | PHARMING GROUP NV | 47.29 | 1.011B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.01B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.008B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 6IV.DE
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
IPO: 2017-02-15
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 84
Phone: 33380447500
INVENTIVA SA / 6IV.DE FAQ
Can you describe the business of INVENTIVA SA?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the stock price of INVENTIVA SA today?
The current stock price of 6IV.DE is 4.77 EUR. The price increased by 3.14% in the last trading session.
Does INVENTIVA SA pay dividends?
6IV.DE does not pay a dividend.
What is the ChartMill rating of INVENTIVA SA stock?
6IV.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of INVENTIVA SA (6IV.DE)?
INVENTIVA SA (6IV.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.29).
Can you provide the market cap for INVENTIVA SA?
INVENTIVA SA (6IV.DE) has a market capitalization of 990.78M EUR. This makes 6IV.DE a Small Cap stock.
What is the ownership structure of INVENTIVA SA (6IV.DE)?
You can find the ownership structure of INVENTIVA SA (6IV.DE) on the Ownership tab.